Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998095 | 0.81 | TGFBR1 (0.41) | TGFBR1CYP1A2CYP2C9POLBKDM4E | |
| SCHEMBL2177180 | 0.79 | KEAP1 (0.46) | TGFBR1CYP1A2CYP2C9POLBKDM4E | |
| SCHEMBL13745284 | 0.79 | TGFBR1 (0.40) | TGFBR1CYP1A2CYP2C9POLBKDM4E | |
| SCHEMBL22521445 | 0.75 | PRMT5 (0.37) | ESR1KDM4EGLAGAA | |
| SCHEMBL18069376 | 0.74 | TGFBR1 (0.41) | TGFBR1CYP1A2CYP2C9POLBKDM4E | |
| SCHEMBL17754846 | 0.73 | TGFBR1 (0.43) | TGFBR1CYP1A2CYP2C9POLBKDM4E | |
| SCHEMBL20844830 | 0.73 | KIT (0.43) | TGFBR1GRM2ADORA2AADORA2BADORA1 | |
| SCHEMBL10238918 | 0.72 | CYP1A2 (0.56) | TGFBR1CYP1A2CYP2C9POLBKDM4E | |
| SCHEMBL24975703 | 0.71 | TNKS (0.41) | TGFBR1CYP1A2CYP2C9KDM4EGLA | |
| SCHEMBL12998303 | 0.69 | PIK3CA (0.47) | TGFBR1CYP1A2CYP2C9KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11198699-B2 | Compounds targeting PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198699-B2 | Compounds targeting PRMT5 | PRMT5, PRMT1, PRMT6 | TGFBR1 1815/4885ESR1 3920/4885CYP1A2 4244/4885 |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | TGFBR1 1815/4885ESR1 3920/4885CYP1A2 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.